+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?



Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?



Digestive Diseases and Sciences: -



The exponential rise in incidence of esophageal adenocarcinoma (EAC), paired with persistently poor survival, continues to drive efforts to improve and optimize screening and surveillance practices. While advancements in endoscopic therapy have generated a shift in management and significantly improved the outcomes of patients with early-stage EAC, the majority of prevalent EAC continues to be diagnosed at advanced stages, remaining ineligible for curative therapy. Barrett's esophagus (BE) screening, when applied to high-yield target populations, using minimally or noninvasive accurate tests, followed by endoscopic surveillance to detect prevalent or incident dysplasia/EAC (which can then be treated successfully) is the cornerstone of the current BE management paradigm. While supported by some empiric evidence and attractive, this approach faces a number of challenges, which are also balanced by numerous recent advances in these areas. In this manuscript, we review the rationale, supportive evidence, current challenges, and recent progress in BE screening and surveillance.

(PDF emailed within 0-6 h: $19.90)

Accession: 065412900

Download citation: RISBibTeXText

PMID: 29713986

DOI: 10.1007/s10620-018-5065-9


Related references

Point-counterpoint. Mass population skin cancer screening can be worthwhile--(if it's done right). Journal of Cutaneous Medicine and Surgery 2(3): 129-132, 1998

Point-counterpoint. Mass population skin cancer screening is not worthwhile. Journal of Cutaneous Medicine and Surgery 2(3): 128-129, 1998

Are screening and surveillance for Barrett's oesophagus really worthwhile?. Gut 54 Suppl 1: I27-I32, 2005

Cancer surveillance in Barrett's esophagus: what is the end point?. Gastroenterology 106(1): 275-277, 1994

Screening and surveillance for Barrett esophagus. JAMA Internal Medicine 175(2): 159-160, 2015

Screening and surveillance of Barrett's esophagus. Current Gastroenterology Reports 11(3): 195-201, 2009

How far to go? Screening and surveillance in Barrett's esophagus. American Journal of Managed Care 7(1 Suppl): S19-S26, 2001

Screening for and surveillance of Barrett's esophagus is clinically indicated. Digestive Diseases 25(3): 197-202, 2007

Barrett's esophagus: novel strategies for screening and surveillance. Therapeutic Advances in Chronic Disease 10: 2040622319837851, 2019

Surveillance and screening for Barrett esophagus and adenocarcinoma. Journal of Clinical Gastroenterology 39(4 Suppl 2): S33-S41, 2005

Not all of Barrett's esophagus surveillance protocols are created equal: the dangers of retrospective outcome research in the treatment of Barrett's esophagus. Gastrointestinal Endoscopy 80(6): 1203, 2015

Screening and surveillance in Barrett's esophagus: a call to action. Clinical Gastroenterology and Hepatology 2(10): 861-864, 2004

The field effect in Barrett's esophagus: can we use it for screening and surveillance?. Endoscopy 45(12): 989-991, 2014

Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies. Gut and Liver 1(2): 93-100, 2007

Barrett's esophagus: update on screening, surveillance, and treatment. Archives of Internal Medicine 159(13): 1411-1416, 1999